A pandemic (H1N1) 2009 virus strain carrying the D222G mutation was identifi ed in a severely ill man and was transmitted to a household contact. Only mild illness developed in the contact, despite his obesity and diabetes. The isolated virus reacted fully with an antiserum against the pandemic vaccine strain.
O n November 20, 2009, the Norwegian Institute of Public Health reported to the World Health Organization a mutation in the hemagglutinin (HA) of pandemic (H1N1) 2009 virus, consisting in a change of aspartic acid (D) with glycine (G) at aa 222. The mutation had been detected in 3 patients (the fi rst 2 fatal cases in the country and in 1 patient with severe pneumonia) among ≈70 other patients with pandemic (H1N1) 2009, suggesting that it was not widespread in Norway (1) . The same mutation has been also detected in Brazil, China, Japan, Mexico, Ukraine, the United States, France, and Spain (1, 2) .
The D-to-G mutation among the 1918 infl uenza virus variants (3) correlated with a shift from α2-6-linked sialic acid preference to a dual α2-3/α2-6 specifi city. However, whether such a mutation may alter receptor binding specifi city in the pandemic (H1N1) 2009 virus is unknown.
Although several pandemic (H1N1) 2009 viral strains sharing this mutation were detected in fatal cases, the same mutation also was detected in some mild cases; conversely, viruses from numerous fatal cases have not shown the same mutation. Thus, the clinical and public health signifi cance of this fi nding remains unclear. The mutation appears to occur sporadically and spontaneously. No links between the small number of patients infected with the mutated virus have been found, and the mutation did not appear to spread (4) . On the basis of results from a retrospective HA1 sequence analysis performed on pandemic (H1N1) 2009 viral isolates in Italy, we report on a transmission event of this virus carrying the D222G mutation.
The Study
We reexamined the HA sequences of 130 infl uenza A (H1N1) virus strains identifi ed from patients affected by pandemic (H1N1) 2009. The neuraminidase sequences of some of these viruses also have been analyzed.
All 130 strains had been obtained from clinical samples (nasal, pharyngeal, or nasopharyngeal swabs and/or tracheal aspirates) collected during May-November 2009 in the context of virologic surveillance conducted by the National Infl uenza Centre, in collaboration with the regional laboratory network. These samples were obtained aimed to study the evolution of the pandemic strain. Forty-one HA gene sequences examined in the present study were retrieved from the National Center for Biotechnology Information, 3 from the Global Initiative on Sharing Avian Infl uenza Data database, and 86 HA sequences (47 directly from the clinical samples and 39 from cell culture supernatant) were obtained at the National Infl uenza Centre (NIC) with the following procedure. Viral RNAs were extracted by using the QIAamp Viral RNA Mini Kit (QIAGEN, Santa Clara, CA, USA) and amplifi ed by reverse transcription-PCR (RT-PCR) (5) . HA amplicons were sequenced by using the BigDye Terminator Cycle-Sequencing Ready Reaction (Applied Biosystems, Foster City, CA, USA) and ABI Prism 310 DNA sequencer (Applied Biosystems). All the NIC sequences were deposited in the GenBank database under the accession numbers reported in the Figure. Sequences were assembled and aligned using Lasergene package, version 4.0 (DNASTAR, Madison, WI, USA). BioEdit software version 4.0 (www.mbio.ncsu.edu/BioEdit/bioedit.html) of the MEGA software package (www.megasoftware.net) was used to estimate phylogenies from the nucleotide sequences and to construct phylogenetic trees by using the neighborjoining algorithm and maximum-likelihood method.
Among 130 patients, 23 of whom had severe disease (i.e., requiring hospitalization), only 1 was infected with a virus showing the D222G change. The patient, a man 25 years of age from northern Italy, had a febrile illness on August 17. One week later, he was admitted to an intensive care unit with severe pneumonia and acute respiratory distress syndrome, which resolved after treatment with extracorporeal membrane oxygenation. Infl uenza A (H1N1) viral genome showing the D222G mutation was identifi ed through direct sequencing of nasopharyngeal swab and tracheal aspirate collected on August 27. No sequence could be retrieved from a nasal wash, which was obtained the same day and was positive in real-time RT-PCR for pan-demic (H1N1) 2009 virus. No viral growth was detected in MDCK cells seeded with both clinical samples.
To identify possible transmission chains of the mutated virus, we analyzed the genome of the viral strain detected in the throat swab of the father of the index case-patient, 55 years of age, who was obese and had diabetes. He became moderately ill on August 25 but did not require hospitalization or antiviral treatment. The virus isolated in MDCK cells from the sample obtained on August 27 had the same HA mutation, D222G. Viral strains from index and contact cases were susceptible to oseltamivir, as determined by lack of the specifi c oseltamivir-resistance marker (His274Tyr, N2 numbering) in neuraminidase sequences, which were identical in both viral strains. Additional samples analyzed from close contacts (i.e., 4 healthcare workers, 4 family members, and 2 friends) of the 2 patients all were negative for pandemic (H1N1) 2009 virus.
Comparison of the 2 HA1 sequences from the index case-patient and his father showed an additional substitution in the latter (G155E), which is located close to the receptor-binding pocket. Furthermore, sequence analyses showed that all virus strains containing a change in HA1 position 222 (D222G or D222E) also showed a second substitution in position 203 (D203T), when compared with the A/California/7/2009 vaccine strain (Figure) . However, the effect of this second mutation on the HA receptor-binding properties is still unclear. The HA1 genes from the index and contact case-patients shared 2 additional nucleotide changes, 1 synonymous substitution (T504C, N1 numbering) not found in any other sequence analyzed in the present study and another nucleotide change resulting in an amino acid substitution (P297S, N1 numbering), detected only in a small number of sequences from Italy. Hemagglutinationinhibition test of the isolated virus did not show substantial reduction in its reactivity with an antiserum against pandemic (H1N1) 2009 vaccine, as compared with the reactivity of an infl uenza virus A/California/7/2009 strain not carrying the G155E mutation (Table) .
Conclusions
Identifi cation of a pandemic (H1N1) 2009 virus strain carrying the D222G mutation and its association with the fi rst fatal cases of infl uenza in Norway raised some concern about emergence of a viral strain with increased pathogenicity. No data have been reported on transmission capacity of this and other D222G variants, occasionally identifi ed worldwide. Our fi ndings suggest that the D222G mutated virus is to some extent transmissible. However, a number of close contacts were identifi ed who did not acquire the infection.
Whether the mutated virus may have a lower fi tness for receptors in the high respiratory tract, which may affect transmission, remains undefi ned. Furthermore, the muta- The NIC-ISS sequences are in italics. Isolates from the index case-patient and his father are indicated in boldface. Amino acid mutations of interest in this study are reported on the nodes. All the NIC sequences obtained in the present study were deposited in the GenBank database under the following accession numbers: (hemagglutinin sequences) GU451262-GU451280; GU576500-GU576502; GU576504; GU576506; GU576508; GU576510; GU576512; GU576514-GU57615; GU576517; GU576519; GU576521-GU576522; GU576524; GU576526-GU576527; GU576529; GU576531-GU576532; GU576534; GU576536-GU576540; GU585403-GU585443; (neuraminidase sequences) GU936490-GU936491. Scale bar indicates proportion of nucleotide substitutions per site. tion, which was fi rst found in a severely affected man, was transmitted to a family member (father), who had only a mild illness, despite risk for severe infection. The HA1 sequence from this latter case presented an additional amino acid substitution (G155E), which was not found in any other sequence analyzed in our study and rarely detected among all sequences available from GenBank. Recent data suggest that amino acid substitution at this position may be critical for the switch from dual α2-3/α2-6 binding specifi city to α2-6 linkage (6), which is preferentially recognized by human infl uenza viruses and expressed mainly in the upper respiratory tract. This change might be partially responsible for the milder infl uenza illness developed by the father of the index case-patient. In addition, the G155E mutation in laboratory-generated variants of pandemic (H1N1) 2009 virus has been associated with loss of antigenicity (7) . In our study, the natural isolates of the virus carrying both the G155E and the D222G mutations had comparable antigenicity with the A/California/7/09-vaccine strain. Finally, our data do not support the association of the D222G mutation with severe disease.
Members of the Surveillance Group for Pandemic A(H1N1)
2009 Infl uenza Virus in Italy: Istituto Superiore di Sanitá (ISS) (National Institute of Health): Livia Di Trani, Annapina Palmieri, and Concetta Fabiani; Regional Laboratories (director name in parentheses): Istituto di ricovero e cura a carattere scientifi co, Rome (Maria R. Capobianchi); Catholic University, Rome (Giovanni Fadda); Padua (Giorgio Palù); Florence (Alberta Azzi); Palermo (Fabio Tramuto); Triest (Pierlanfranco D'Agaro); Cosenza (Cristina Giraldi); Naples (Ciro Esposito); Ancona (Patrizia Bagnarelli); Turin (Valeria Ghisetti); and Genoa (Filippo Ansaldi).
